Literature DB >> 29622881

Safety of Zoledronic Acid in Patients with Thalassemia Associated Low Bone Mineral Density.

Rahul Naithani1,2, Tulika Seth2, Nikhil Tandon3, Jagdish Chandra4, H Pati2, V P Choudhry2.   

Abstract

Entities:  

Year:  2017        PMID： 29622881      PMCID： PMC5884980          DOI： 10.1007/s12288-017-0858-0

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


× No keyword cloud information.
  5 in total

1.  Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial.

Authors:  Ersi Voskaridou; Dimitrios Christoulas; Marialena Konstantinidou; Evangelos Tsiftsakis; Panagiotis Alexakos; Evangelos Terpos
Journal:  Haematologica       Date:  2008-08-12       Impact factor: 9.941

2.  Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.

Authors:  Vassilios Perifanis; Timoleon Vyzantiadis; Konstantinos Tziomalos; Sofia Vakalopoulou; Vassilia Garipidou; Miranda Athanassiou-Metaxa; Faidon Harsoulis
Journal:  Ann Hematol       Date:  2006-09-30       Impact factor: 3.673

3.  Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.

Authors:  Zaher K Otrock; Sami T Azar; Wael A Shamseddeen; Dany Habr; Adlette Inati; Suzane Koussa; Rami A R Mahfouz; Ali T Taher
Journal:  Ann Hematol       Date:  2006-07-08       Impact factor: 3.673

4.  Fractures and Low Bone Mineral Density in Patients with Beta Thalassemia Major.

Authors:  Rahul Naithani; Tulika Seth; Nikhil Tandon; Jagdish Chandra; H Pati; Renu Saxena; V P Choudhry
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-22       Impact factor: 0.900

Review 5.  Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature.

Authors:  Naim M Maalouf; Howard J Heller; Clarita V Odvina; Peter J Kim; Khashayar Sakhaee
Journal:  Endocr Pract       Date:  2006 Jan-Feb       Impact factor: 3.443
  5 in total
  1 in total

1.  Zoledronic Acid for Treatment of Low Bone Mineral Density in Patients with Beta Thalassemia Major.

Authors:  Rahul Naithani; Tulika Seth; Nikhil Tandon; Jagdish Chandra; V P Choudhry; H Pati; Renu Saxena
Journal:  Indian J Hematol Blood Transfus       Date:  2018-03-27       Impact factor: 0.900
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.